Supplementary Table 1. Stability over up to 5 years of 14-3-3η, RF, ACPA and CRP status (positive or negative)

At baseline	Over follow up duration*	14-3-3η ≥0.50 ng/ml (High-14-3-3η)	ACPA positive (ACPA)	RF positive (RF)	CRP >8.0 mg/L (High-CRP)
		n (%)	n (%)	n (%)	n (%)
	Total	219	252	273	412
Positive	Remained positive	85 (38.8)	218 (86.5)	146 (53.5)	56 (13.6)
	Became stably negative**	73 (33.3)	23 (9.1)	67 (24.5)	271 (65.8)
	Became negative only once	48 (21.9)	11 (4.4)	56 (20.5)	64 (15.5)
	Unstable***	13 (5.9)	0 (0)	4 (1.5)	21 (5.1)
	Total	429	449	432	294
Negative	Remained negative	264 (61.5)	419 (93.3)	400 (92.6)	219 (74.5)
	Became stably positive**	39 (9.1)	16 (3.6)	13 (3.0)	18 (6.1)
	Became positive only once	108 (25.2)	14 (3.1)	17 (3.9)	53 (18.0)
	Unstable***	18 (4.2)	0 (0)	2 (0.5)	4 (1.4)

^{*} The maximal number of evaluable visits per patient was 2 in 73, 70, 70 and 59 patients; 3 in 83, 247, 81, and 73; 4 in 131, 215, 146, and 128; and 5 in 361, 169, 408 and 446 patients for 14-3-3η, ACPA, RF and CRP, respectively. ** Changed status (positive to negative or negative to positive) and remained so for at least 2 consecutive visits

^{***} Unstable means that status (positive or negative) was variable from one visit to the other.